Navigation Links
Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announced that an interim report regarding the clinical study of BF-200 ALA in actinic keratosis was received today from an independent review committee. The objectives of the study are to investigate the efficacy and safety of several doses of BF-200 ALA in photodynamic therapy. The comments received today refer to the clinical results eight weeks after treatment. An additional report about the results after twelve weeks will follow.

The interim committee reported that no side effect justifying concerns about the safety of this dose were observed in any dose group. On the basis of the available data, the therapy was found to be safe for all doses tested.

In spite of the limited patient number, different doses gave rise to clear differences in efficacy. However, the results of the different doses were not yet disclosed. The committee announced this disclosure once it has received and analyzed the clinical results 12 weeks after treatment. Biofrontera expects this second report within few weeks.

To optimize the statistical study design, the committee has proposed to continue the phase III part of the study separately. This will enable the complete analysis of the 12-week data. On this basis, Biofrontera intends to continue the further development of the 10 % dose, provided this dose selection is supported by the 12-week data.

Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Germany ISIN: DE0006046113 WKN: 604611

Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 222 Fax.: +49 (0214) 87 63 290 e-mail: a.zurmuehlen@biofrontera.com


'"/>




Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: hoc Interim report about clinical trial ALA actinic keratosis
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... YORK and HERZLIYA PITUACH, Israel, Nov. 25, ... "Immune" or "the Company"), a clinical stage biopharmaceutical ... of targeted therapeutics for the treatment of inflammatory ... its previously announced underwritten public offering of 3,450,000 ... of the Company,s common stock, par value $0.0001 ...
(Date:11/24/2014)... SAN DIEGO , Nov. 24, 2014  Arena Pharmaceuticals, ... is scheduled to present a corporate overview and update at ... Tuesday, December 2, 2014, at 8:30 a.m. Eastern Time (5:30 ... New York . A live ... investor relations section of Arena,s website at www.arenapharm.com . ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 3
... N.J., March 8, 2012  Janssen Research & Development, ... Phase 3 study of ZYTIGA® (abiraterone acetate) plus ... symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) ... Study COU-AA-302 is an international, randomized, double-blind, placebo ...
... AMSTERDAM, March 8, 2012  Leading events organiser UBM Live ... announced an addition to the CPhI Japan events line-up ... Sight Exhibition Centre from 21-23 March, 2012. The Pharmatech ... technology for the Pharma, biopharma, veterinary and medical industries, ...
Cached Medicine Technology:Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 2Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 3Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 4Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 5Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer 6New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 2New Pharmatech Event to be Introduced Alongside CPhI and P-MEC Japan 3
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
(Date:11/26/2014)... 26, 2014 Sonru, the video interviewing ... Chief Operating Officer and Chief Marketing Officer, in addition ... , Jeff Jones has been appointed as Chief ... takes the role of Chief Marketing Officer. , Mr ... whose 25-year career includes senior roles with The Walt ...
(Date:11/26/2014)... November 26, 2014 Call 866-997-4948 (Us-Canada ... or email the details on sales(at)researchmoz(dot)us , Researchmoz.us ... drug discovery market 2014" with deep study of the ... result of high blood sugar. The global glucose monitoring ... to the growing number of diabetics in the world. ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 For those with ... new LES MILLS BODYPUMP™ classes at the University ... the workout they've been looking for. The 45- 60 minute ... Anschutz Health and Wellness Center fitness club memberships. , LES ... workouts are fast-paced and are aimed at fast results ...
(Date:11/26/2014)... 26, 2014 Sonoran Vein and ... received the Distinguished Preceptorship Award from The ... role in the advancement of nurse practitioners. The ... individual who had made a significant contribution toward ... American Association of Nurse Practitioners (AANP) is the ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5Health News:Sonru Expansion continues with appointment of new executive team and opening of new London base 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:LES MILLS BODYPUMP™ classes come to the University of Colorado Anschutz Health and Wellness Center 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2
... an efficient, effective way to analyze wounds from bullets and ... the March issue of Radiology . "The ... care and aid in both military and civilian forensic investigations," ... from the Uniformed Services University in Bethesda, Md. U.S. ...
... Extremely obese people had a significantly greater chance of dying ... that became a pandemic last winter, a new study reports. ... with H1N1 flu during the first four months of 2009 ... three-fold increased risk for death. Extreme obesity is defined ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, Jan. ... the risk of autism in the second child, new research ... within a year of their older sibling. Babies conceived within ... their older sibling were also at a heightened risk of ...
... HealthDay Reporter , MONDAY, Jan. 10 (HealthDay News) -- Widespread ... a 5 percent drop in available nursing home beds across ... research reveals. "The country,s minority population is aging at ... lead author Zhanlian Feng, an assistant professor of community health ...
... is well known that pain is a highly subjective experience. ... depending on distractions and mood. A paper in the ... cautionary note on measuring perceived pain in research. There ... symptoms other than pain, but because of the subjectivity in ...
... report a gene therapy strategy that improves the condition ... Beta Thalassemia. The gene correction involves using unfertilized ... embryonic stem cell lines. Some of these stem cell ... thus be used for transplantation-based treatments of the same ...
Cached Medicine News:Health News:CT helps identify bullet trajectories 2Health News:Closely Spaced Pregnancies Might Up Autism Risk: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 2Health News:U.S. Nursing Home Closings Hit Poor Neighborhoods Hardest: Study 3Health News:Does it hurt? 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 2Health News:Embryonic stem cells help deliver 'good genes' in a model of inherited blood disorder 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: